NASDAQ:UTHR - United Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$107.89 -2.26 (-2.05 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$110.15
Today's Range$107.51 - $110.97
52-Week Range$100.57 - $152.55
Volume398,900 shs
Average Volume382,981 shs
Market Capitalization$4.88 billion
P/E Ratio9.91
Dividend YieldN/A
Beta1.24
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension; and a licensing and commercialization agreement with Collplant for 3D bioprinting of solid-organ scaffolds for human transplants. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
Previous Symbol
CUSIP91307C10
Phone301-608-9292

Debt

Debt-to-Equity Ratio0.09
Current Ratio4.32
Quick Ratio4.05

Price-To-Earnings

Trailing P/E Ratio9.91
Forward P/E Ratio7.56
P/E Growth26.15

Sales & Book Value

Annual Sales$1.73 billion
Price / Sales2.73
Cash Flow$11.5886 per share
Price / Cash Flow9.31
Book Value$48.64 per share
Price / Book2.22

Profitability

EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins31.73%
Return on Equity25.24%
Return on Assets19.56%

Miscellaneous

Employees800
Outstanding Shares43,590,000
Market Cap$4.88 billion
OptionableOptionable

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics' stock buyback program work?

United Therapeutics declared that its board has initiated a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 4.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, October, 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the consensus estimate of $3.23 by $0.81. The biotechnology company had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. United Therapeutics's revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.69 EPS. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 12-month price targets for United Therapeutics' shares. Their forecasts range from $95.00 to $253.00. On average, they anticipate United Therapeutics' share price to reach $135.00 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

What are Wall Street analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%." (11/1/2018)
  • 2. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. The acquisition of SteadyMed added its drug device pipeline product Trevyent to its portfolio, which could have posed competition to Implantable System for Remodulin (ISR) which was approved recently in July with a launch scheduled for 2019. However, competition in the PAH market is increasing. Also two of its biggest products - Remodulin and Adcirca – are expected to face generic competition this year. United Therapeutics’ shares have also underperformed the industry so far this year." (10/22/2018)

Has United Therapeutics been receiving favorable news coverage?

Media stories about UTHR stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. United Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near term.

Who are some of United Therapeutics' key competitors?

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 46)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 50)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Kevin Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.29%), Vanguard Group Inc. (8.66%), Vanguard Group Inc (8.66%), FMR LLC (6.74%), AQR Capital Management LLC (5.34%) and Renaissance Technologies LLC (4.46%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, MERIAN GLOBAL INVESTORS UK Ltd, Skandinaviska Enskilda Banken AB publ, JPMorgan Chase & Co., JPMorgan Chase & Co., Schroder Investment Management Group, BlackRock Inc. and Capital Fund Management S.A.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.

Which major investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, AQR Capital Management LLC, Prudential Financial Inc., Mackenzie Financial Corp, Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V. and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $107.89.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $4.88 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  518 (Vote Underperform)
Total Votes:  901
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Featured Article: 52-Week High/Low

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel